Eli lilly and company LLY.US 總覽分析

美股醫療保健

LLY 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分較低,不過公司股利評分優異,若想穩定收息,仍可以考慮持續持有。但若僅以價值投資為目標可以減碼換股操作

LLY 近期報酬表現

-1.30%

Eli lilly and company

0.94%

同產業平均

0.41%

S&P500

與 LLY 同產業的標的表現

  • NVO Novo nordisk as
    價值 2 分趨勢 1 分波段 4 分籌碼 3 分股利 5 分
    查看更多

LLY 公司資訊

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of ?4?7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

LLY 股價